Skip to main content

For Healthcare Professionals

Site Menu

  • Press
  • About Us
  • Global Website
  • Contact
  • English

Search for product, molecule, disease…

User account menu

  • Log in
Home
  • Therapeutic Areas
    • CMR
  • Products
    • Jentadueto®
    • Trajenta®
  • Diseases
    • Diabetes
  • LogIn

Search for product, molecule, disease…

Resources

  • Publication: CARMELINA Elderly Subgroup Analysis [1]

    Review the long-term safety profile of Trajenta® among age groups.
    See our infographic
    White elderly female Diabetes patient painting

  • Publication: CAROLINA Asian Subgroup Analysis [2]

    Review the long-term safety profile of Trajenta® in Asian patients.
    See our infographic
    Asian middle-aged male Diabetes patient gardening

  • Simple. Every Day.

    When a DPP4i is needed, choose the Simplicity of Trajenta®.
    Continue below
    White middle-aged male Diabetes patient jogging

  • 10 Years of Simplicity

    Browse through an interactive infographic showcasing the clinical development and significant accomplishments for Trajenta®.
    See the infographic
    10 Years of Simplicity Banner

Trajenta®(linagliptin)

  • Simplicity
  • Efficacy
  • Safety Profile
  • Dosing
  • Resources
  • SmPC
  • Events
Watch. Download. Learn.

We appreciate that you have taken the time to learn more about Trajenta®. That is why we have collected a variety of resources related to Trajenta® and how its Simplicity can help you in your daily management of type 2 diabetes patients. Continue below or use the quick links below to find the right resource.

 

Expert VideosFirsthand experience from international diabetes experts.

Webcast VideosSee video clips about Trajenta® from previous events.

CVOT Videos Let our video series guide you through CVOT data.

Infographics Explore infographics about our CVOT program.

10 Years of SimplicityReview materials celebrating the first 10 years of Trajenta®.

ExploratoriumDive into an immerse experience with Trajenta® data.

Press Releases Stay up-to-date with the latest news on Trajenta®.

EXPERT VIDEOS

Video of Professor Cummings from the UK speaking about Trajenta
Prof. Cummings (Portsmouth, UK)
Simplicity of Trajenta® within the DPP4i class.
Video of Professor Cummings from the UK speaking about Trajenta
Prof. Cummings (Portsmouth, UK)
Trajenta® consistently lowers HbA1c.
Video of Professor Jodar from Spain speaking about Trajenta
Prof. Jodar (Madrid, Spain)
CARMELINA® is a unique CVOT in the DPP4i class.
Video of Professor Jodar from Spain speaking about Trajenta
Prof. Jodar (Madrid, Spain)
CAROLINA® cardiovascular safety of linagliptin.
Video of Professor Davies from the UK speaking about Trajenta
Prof. Davies (Leicester, UK)
Linagliptin simplifies T2D treatment.
Video of Professor Frankel from the UK speaking about Trajenta
Prof. Frankel (London, UK)
CV and kidney safety profile of Trajenta®.
Video of Professor Frankel from the UK speaking about Trajenta
Prof. Frankel (London, UK)
Convenience of 5mg once daily.
Video of Professor Kalra from India speaking about Trajenta
Prof. Kalra (Karnal, India)
Trajenta® for a broad range of T2D patients.
Video of Professor Groop from Finland speaking about Trajenta
Prof. Groop (Helsinki, Finland)
Linagliptin benefits for T2D patients.

WEBCAST VIDEOS

A unique CVOT programme – spotlight on CARMELINA
Prof. Marx (Aachen, Germany)
A unique CVOT programme - spotlight on CARMELINA
A unique CVOT programme – spotlight on CARMELINA adverse events
Prof. Marx (Aachen, Germany)
A unique CVOT programme - spotlight on CARMELINA adverse events
A unique CVOT programme – spotlight on CAROLINA
Prof. Marx (Aachen, Germany)
A unique CVOT programme - spotlight on CAROLINA
An extensive dataset from a unique CVOT programme
Prof. Marx (Aachen, Germany)
An extensive dataset from a unique CVOT programme.
Linagliptin for a broad range of patients – spotlight on efficacy data
Prof. Groop (Helsinki, Finland)
Linagliptin for a broad range of patients – spotlight on efficacy data
Spotlight on efficacy of linagliptin in a broad range of patients
Prof. Groop (Helsinki, Finland)
Spotlight on efficacy of linagliptin in a broad range of patients
Linagliptin for a broad range of patients – spotlight on safety data
Prof. Groop (Helsinki, Finland)
Linagliptin for a broad range of patients - spotlight on safety data
Can a broad range of T2D patients benefit from the simplicity of linagliptin
Prof. Groop (Helsinki, Finland)
Can a broad range of T2D patients benefit from the simplicity of linagliptin?
Defining simplicity in clinical practice – a case-driven approach
Dr. Jarvis (London, England)
Defining simplicity in clinical practice – a case-driven approach.
Summarising the advances that linagliptin has brought to T2D care
Prof. Groop (Helsinki, Finland)
Summarising the advances that linagliptin has brought to T2D care.

CVOT VIDEOS

Trajenta global outcome program supporting cardiovascular and kidney safety profile
CVOT Overview

A comprehensive overview of the CVOT program.

CARMELINA assessed the cardiovascular and kidney safety profile of Trajenta
CARMELINA®

Dive deeper into the CARMELINA® trial.

CAROLINA assessed the cardiovascular safety profile of Trajenta
CAROLINA®

Explore the CAROLINA® trial.

INFOGRAPHICS

White elderly female Diabetes patient painting
CARMELINA® and CAROLINA®

Subgroup Analysis of Elderly Patients.

Asian middle-aged male Diabetes patient gardening
CARMELINA® and CAROLINA®

Subgroup Analysis of Asian Patients.

10 YEARS OF SIMPLICITY

10 Years of Simplicity Infographic, from 2011 to 2021
10 YEAR ANNIVERSARY
Key milestones for the first 10 years of Trajenta®, from 2011 to 2021.
10 Years of Simplicity Infographic, before launch
10 YEAR ANNIVERSARY
Key milestones leading up to the registration of Trajenta® in 2011.
10 Years of Simplicity Interactive Infographic
10 YEAR ANNIVERSARY
Interactive exploration of key milestones in the history of Trajenta®.
A video developed to highlight the 10-year history of Trajenta
10 YEAR ANNIVERSARY
A video developed to highlight the 10-year history of Trajenta®.

EXPLORATORIUM

Explore extensive efficacy data of Trajenta for a broad range of patients
Explore. Efficacy.
Explore extensive efficacy data of Trajenta® for a broad range of patients.
Explore a summary of the key characteristics of Trajenta
Explore. Experience.
Explore a summary of the key characteristics of Trajenta®.
Explore the convenient dosing of Trajenta and Jentadueto
Explore. Dosing.
Explore the convenient dosing of Trajenta® and Jentadueto®.
Explore extensive cardiovascular and renal safety data of Trajenta
Explore. Safety Profile.
Explore extensive cardiovascular and renal safety data of Trajenta®.

PRESS RELEASES

Note: below you may find press releases about Trajenta® that were issued prior to January 1, 2020. Prior to this date, Boehringer Ingelheim and Eli Lilly and Company jointly commercialised Trajenta®. Since the beginning of 2020, Boehringer Ingelheim remains the sole entity responsible for commercialisation of Trajenta® worldwide. All inquiries related to Trajenta® should be directed to Boehringer Ingelheim.

Image of a mocked-up press release
February 2020

CARMELINA® subgroup analysis published.

Image of a mocked-up press release
June 2019

Full data from CAROLINA®.

Image of a mocked-up press release
February 2019

CAROLINA® meets primary endpoint.

Image of a mocked-up press release
October 2018

Full results of CARMELINA®.

Image of a mocked-up press release
July 2018

CARMELINA® met its primary endpoint.

  1. Boehringer Ingelheim
  2. HCP Portal
  3. Products
  4. Trajenta®
  5. Resources

Footer menu

  • Sitemap
  • Accessibility Statement
  • Terms of Use
  • Imprint
  • Cookie Policy
  • Privacy Policy
© 2022 Boehringer Ingelheim International GmbH. All rights reserved.
© 2022 Boehringer Ingelheim International GmbH.
All rights reserved.